BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 26 Oct, 16:06 UTC

The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.

science

Sources

• T2BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyBioPharma Dive / Healthcare Dive / MedTech Dive26 Oct, 16:06